The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study

被引:85
|
作者
Yang, WH
Drouin, MA
Herbert, M
Mao, Y
Karsh, J
机构
[1] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[2] HLTH CANADA, LAB CTR DIS CONTROL, OTTAWA, ON K1A 0L2, CANADA
[3] HLTH CANADA, BUR CHRON DIS EPIDEMIOL, OTTAWA, ON K1A 0L2, CANADA
关键词
monosodium glutamate; monosodium glutamate symptom complex; randomized double-blind challenge;
D O I
10.1016/S0091-6749(97)80008-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Considerable debate swirls about the validity of symptoms described by many people after ingestion of monosodium glutamate (MSG), and the question has remained unresolved largely because of a paucity of well-designed challenge studies. Methods: We conducted oral challenge studies in self-identified MSG-sensitive subjects to determine whether they had a statistically significant difference in the incidence of their specific symptoms after ingestion of MSG compared with placebo. First, 5 gm MSG or placebo was administered in random sequence in a double-blind fashion. Subjects who reacted only to a single test agent then underwent rechallenge in random sequence in a double-blind fashion with placebo and 1.25, 2.5, and 5 gm MSG. A positive response to challenge was defined as the reproduction of greater than or equal to 2 of the specific symptoms in a subject ascertained on prechallenge interview. Results: Sixty-one subjects entered the study. On initial challenge, 18 (29.5%) responded to neither MSG nor placebo, 6 (9.8%) to both, 15 (24.6%) to placebo, and 22 (36.1%) to MSG (p = 0.324). Total and average severity of symptoms after ingestion of MSG (374 and 80) were greater than respective values after placebo ingestion (232 and 56; p = 0.026 and 0.018, respectively). Rechallenge revealed an apparent threshold dose for reactivity of 2.5 gm MSG. Headache (p < 0.023), muscle tightness (p < 0.004), numbness/tingling (p < 0.007), general weakness (p < 0.040), and Bushing (p < 0.016) occurred more frequently after MSG than placebo ingestion. Conclusions: Oral challenge with MSG reproduced symptoms in alleged sensitive persons. The mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism. According to Food and Drug Administration recommendations, the symptoms, originally called the Chinese restaurant syndrome, are better referred to as the MSG symptom complex.
引用
收藏
页码:757 / 762
页数:6
相关论文
共 50 条
  • [21] PREOPERATIVE MULTIMODAL ANALGESIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    KAVANAGH, B
    KATZ, J
    SANDLER, A
    NIERENBERG, H
    ROGER, S
    BOYLAN, J
    ANESTHESIA AND ANALGESIA, 1993, 76 (02): : S182 - S182
  • [22] SIAXI Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
    Jost, Wolfgang H.
    Friedman, Andrzej
    Michel, Olaf
    Oehlwein, Christian
    Slawek, Jaroslaw
    Bogucki, Andrzej
    Ochudlo, Stanislaw
    Banach, Marta
    Pagan, Fernando
    Flatau-Baque, Birgit
    Csikos, Janos
    Cairney, Claire J.
    Blitzer, Andrew
    NEUROLOGY, 2019, 92 (17) : E1982 - E1991
  • [23] Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
    Rammohan, KW
    Lynn, DJ
    NEUROLOGY, 2005, 65 (12) : 1995 - 1996
  • [24] A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis
    Carter, Melody C.
    Maric, Irina
    Brittain, Erica H.
    Bai, Yun
    Lumbard, Keith
    Bolan, Hyejeong
    Cantave, Daly
    Scott, Linda M.
    Metcalfe, Dean D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 1004 - +
  • [25] A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia
    Sabe, L
    Salvarezza, F
    Cuerva, AG
    Leiguarda, R
    Starkstein, S
    NEUROLOGY, 1995, 45 (12) : 2272 - 2274
  • [26] Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study
    Allam, MF
    NEUROLOGY, 2002, 58 (07) : 1133 - 1133
  • [27] Montelukast for migraine prophylaxis: A randomized, double-blind, placebo-controlled study
    Brandes, JL
    Visser, WH
    Farmer, MV
    Schuhl, AL
    Malbecq, W
    Vrijens, F
    Lines, CR
    Reines, SA
    HEADACHE, 2004, 44 (06): : 581 - 586
  • [28] Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine
    Whitmarsh, TE
    ColestonShields, DM
    Steiner, TJ
    CEPHALALGIA, 1997, 17 (05) : 600 - 604
  • [29] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Shervin Taslimi
    Hamed Vahidi
    Ali Pourvaziri
    Amirhossein Modabbernia
    Arezoo Yeke Fallah
    Nasrin Yazdani
    Negin Taslimi
    Mostafa Hosseini
    Masoud Motesadi Zarandi
    European Archives of Oto-Rhino-Laryngology, 2013, 270 : 1635 - 1641
  • [30] Oxcarbazepine in migraine headache - A double-blind, randomized, placebo-controlled study
    Silberstein, S.
    Saper, J.
    Berenson, F.
    Somogyi, M.
    McCague, K.
    D'Souza, J.
    NEUROLOGY, 2008, 70 (07) : 548 - 555